Lumvoa Injection
NDC Package 85166-001-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lumvoa (veligrotug) injection is lUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. This formulation utilizes a injection delivery system. Marketed by Viridian Therapeutics, Inc., this product is identified by NDC 85166-001 and is authorized under FDA application BLA761530.

Identification & Billing

NDC Package Code
85166-001-01
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE
Product Code
85166-001
11-Digit Billing Format
85166000101

Clinical Specifications

Proprietary Name
Lumvoa
Non-Proprietary Name
Veligrotug
Substance Name
Veligrotug
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
VELIGROTUG 50 mg/mL
Usage Information
LUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.

Regulatory & Marketing

Labeler Name
Viridian Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761530
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-26-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 85166-001-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 10 ml in 1 vial, single-dose of Lumvoa, a human prescription drug labeled by Viridian Therapeutics, Inc.. This injection is formulated for intravenous use and contains veligrotug as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viridian Therapeutics, Inc. on June 26, 2026. The current certification is valid through December 31, 2027.

How is this Viridian Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 85166000101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
85166-001-01
11-Digit CMS (5-4-2)
85166-0001-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.